Literature DB >> 11448913

Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification.

K Seki1, T Suda, Y Aoyagi, S Sugawara, M Natsui, H Motoyama, Y Shirai, T Sekine, H Kawai, Y Mita, N Waguri, T Kuroiwa, M Igarashi, H Asakura.   

Abstract

PURPOSE: We evaluated the diagnostic efficacy of detection of human telomerase reverse transcriptase (hTERT) message, a catalytic domain of human telomerase, in endoscopic retrograde pancreatography (ERP)-derived pancreatic juice. EXPERIMENTAL
DESIGN: Both hTERT and CD25 expression were detected by reverse transcription-PCR (RT-PCR) in 17 patients with pancreatic adenocarcinoma (PC), 12 patients with chronic pancreatitis (CP), and 7 patients with no ERP abnormality (N). In the same patients, beta-actin message was semiquantified by competitive RT-PCR. K-ras codon 12 mutations were concomitantly analyzed by enriched PCR-SSCP in 11 and 7 PC and CP cases, respectively.
RESULTS: Expression of hTERT was detected in 88% of PC cases and 17% of CP cases but not in the normal control (N). Alterations in K-ras were detected in 73% of PC cases and 57% of CP cases, respectively. beta-Actin mRNA was expressed in >3.0 x 10(1) copies/microl in all but two PC cases in which hTERT mRNA was not detected. CD25-positive and -negative peripheral lymphocytes were isolated from a normal volunteer using a fluorescent activating cell sorter. The hTERT message was detected in CD25-positive peripheral lymphocytes and in 18, 25, and 0% of the pancreatic juice samples from PC, CP, and N cases, respectively. All CP cases expressing hTERT message were also CD25 positive.
CONCLUSIONS: These results suggest that detection of hTERT mRNA in pancreatic juice is a powerful tool to discriminate PC from CP, particularly when the samples are qualified against beta-actin mRNA levels and contaminating CD25-positive lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448913

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

Review 1.  Molecular markers of pancreatic cancer: development and clinical relevance.

Authors:  Lucia C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

2.  Computational selection and experimental validation of allosteric ribozymes that sense a specific sequence of human telomerase reverse transcriptase mRNAs as universal anticancer therapy agents.

Authors:  Robert Penchovsky; Gergana T Kostova
Journal:  Nucleic Acid Ther       Date:  2013-11-09       Impact factor: 5.486

3.  Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project.

Authors:  Christine A Iacobuzio-Donahue
Journal:  Gut       Date:  2011-07-11       Impact factor: 23.059

Review 4.  Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Authors:  Amedeo Amedei; Elena Niccolai; Domenico Prisco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 5.  Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.

Authors:  Shih-Hung Yang; Ting-Chun Kuo; Hsu Wu; Jhe-Cyuan Guo; Chiun Hsu; Chih-Hung Hsu; Yu-Wen Tien; Kun-Huei Yeh; Ann-Lii Cheng; Sung-Hsin Kuo
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

6.  Relationship between telomerase activity and its subunit expression and inhibitory effect of antisense hTR on pancreatic carcinoma.

Authors:  Jia-Hua Zhou; Hong-Mei Zhang; Quan Chen; Dong-Dong Han; Fei Pei; Li-Shan Zhang; De-Tong Yang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

Review 7.  Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Yoshihiro Matsumoto; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

8.  Quantitative assessment of the diagnostic role of human telomerase activity from pancreatic juice in pancreatic cancer.

Authors:  Siliang Wang; Xiaodong Chen; Meiyue Tang
Journal:  Tumour Biol       Date:  2014-05-15

Review 9.  Current immunotherapeutic approaches in pancreatic cancer.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Shintaro Tsukinaga; Jimi Mitobe; Shunichi Odahara; Toyokazu Yukawa; Hiroshi Matsudaira; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Masaki Ito; Hideo Komita; Hiroshi Arakawa; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2011-09-14

Review 10.  What is recent in pancreatic cancer immunotherapy?

Authors:  Elena Niccolai; Domenico Prisco; Mario Milco D'Elios; Amedeo Amedei
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.